# China Healthcare
Latest news and articles about China Healthcare
Total: 8 articles found
The 30,000-Yuan Red Line: China’s Healthcare Sector Reels Under Strict New Anti-Bribery Rules
China has introduced a strict new judicial interpretation lowering the criminal prosecution threshold for healthcare bribery to 30,000 RMB, triggering widespread panic among doctors and pharmaceutical firms. The move targets both public and private sectors, holding companies liable for employee misconduct and signaling an end to the era of relationship-based medical sales.
Regulatory Renaissance: How New Policy Orders are Unlocking China’s Stem Cell Ambitions
China is implementing a landmark regulatory overhaul to streamline the transition of stem cell research from hospital labs to clinical practice. Centered in Shanghai's Zhangjiang hub, this new policy framework aims to leverage real-world clinical data to establish global leadership in regenerative medicine while enforcing strict ethical and safety standards.
Power Asymmetry and Private Healthcare: Aier Eye Hospital Scandal Sparks Outcry Over Workplace Harassment in China
The director of Hangzhou Aier Eye Hospital has been suspended following allegations of sexually harassing a pharmaceutical sales manager. The case has ignited a national conversation regarding workplace power dynamics, professional retaliation, and the legal challenges victims face in prosecuting harassment in China.
Healing the Frontline: Why a Military Doctor's Empathy is Resonating Across China
The viral story of military doctor Dai Jigang's empathetic care highlights the systemic pressures of China's healthcare system and the unique role of military medicine in maintaining public trust. By offering both in-person and digital consultations, Dai addresses the massive rural-urban divide in medical access.
Beyond the Scalpel: A Military Doctor and the Human Face of China’s Healthcare Strain
Military doctor Dai Jigang has gained national attention for his empathetic treatment of patients and his commitment to offering free online consultations. His actions shed light on the massive disparities in China's healthcare system and the evolving role of PLA medical personnel in civil society.
Navigating the Labyrinth: The Rise and Growing Pains of China’s Medical Companions
China is witnessing the emergence of 'medical companions' to help the elderly and lonely youth navigate a digitized healthcare system. While the industry faces regulatory voids and predatory certification scams, government pilot programs signal a shift toward official professionalization by 2026.
Weiguang Bio Advances Patient-Centric Care with Subcutaneous Immunoglobulin Trial Approval
Weiguang Biological has received NMPA approval to begin clinical trials for a subcutaneous human immunoglobulin injection. The therapy targets primary immunodeficiency diseases and represents a shift toward home-based, patient-friendly administration in the Chinese plasma market.
China’s Fountain of Youth: The Dangerous Rise of the Underground Stem Cell Market
China is witnessing a surge in illegal stem cell infusions marketed as high-priced anti-aging treatments, often involving collusion between private firms and public hospital doctors. Despite costs reaching $55,000 per shot, there is no scientific evidence or regulatory approval for these therapies, posing significant health and financial risks to consumers.